Background: Frontotemporal dementia (FTD) is a neurodegenerative disease with early symptoms of personality change and/or language disorder. Approximately 40% of individuals with FTD have a family history of dementia; however, in our experience, less than 10% have clear autosomal dominant inheritance. Mutations in the microtubule-associated protein tau (MAPT) gene have been reported in up to 50% of hereditary cases, but are unusual except in families with more than 3 individuals with FTD. The genetics of FTD is complicated by clinical heterogeneity, variable expression, phenocopies, misdiagnoses, and lost family histories. The objective of this paper is to enable physicians to recognize hereditary patterns and genetic concerns of FTD families and to understand genetic counseling strategies. Review Summary: The complexity of FTD genetics and genetic counseling are illustrated using 4 case histories. Case 1 demonstrates the difficulty obtaining a reliable FTD family history. Case 2 illustrates how psychiatric phenocopies can make family linkage studies difficult. The lack of genotype and phenotype correlation and
F rontotemporal dementia (FTD) is a neurodegenerative disease affecting cognition, language, personality, and social functioning. FTD is a heterogeneous term encompassing a group of conditions including Pick disease, FTD with parkinsonism related to chromosome 17 (FTDP-17), primary progressive aphasia, and semantic dementia. On autopsy, many FTD cases show neuropathologic changes that involve tau, and are thus considered in the group of neurodegenerative disorders collectively referred to as "tauopathies." 1 Other tauopathies closely related to FTD are corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). Clinical and neuropathologic diagnostic criteria have been defined to assist the clinician in the differential diagnosis of FTD and related tauopathies. 2 Initial clinical features of FTD are characterized by a behavioral/personality disorder or a language disorder (primary progressive aphasia or semantic dementia). Behavioral changes in FTD include emotional blunting, loss of insight, disinhibition, mental rigidity, mood instability, and impaired judgment and executive function. 3, 4 FTD is generally considered a presenile dementia with a mean age of onset between 56 and 62 years (range, 21-80 years). 5, 6 However, subtle personality changes may occur long before the disease becomes fully manifested. 7 FTD is frequently misdiagnosed in its early stages as a psychiatric condition and later as Alzheimer disease (AD). Parkinsonism or motor neuron disease may complicate the clinical presentation of FTD. 4, 6 The prevalence of FTD is unknown. One study has tried to gather prevalence data in a community setting of individuals under the age of 65 in the United Kingdom. In this cohort, the prevalence of FTD and early-onset AD were approximately equivalent-15 per 100,000. 8 Given the study's limited ascertainment, it is likely that FTD is even more prevalent than this report suggests. It may account for as much as 20% of presenile dementia. 9 The genetic contribution to FTD is understood in only a small fraction of the cases. Like many adult-onset neurodegenerative conditions, FTD appears to be a complex, multifactorial condition making pedigree analysis and genetic counseling challenging. Approximately 60% of cases are thought to be sporadic, whereas 40% have some family history of dementia or neurodegenerative disease. 10 Studies differ in the percent of these families demonstrating an autosomal dominant pattern of inheritance with 1 or more affected first-degree relatives of the proband. Chow et al 5 found that 80% of families with positive family histories of dementia showed an autosomal dominant pattern, whereas a Dutch study found 43% of their cohort had a first-degree relative with dementia.
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In 1994, linkage studies of a large family with a form of FTD designated disinhibition-dementia-parkinsonism-amyotrophy complex revealed a significant finding on chromosome 17. [12] [13] [14] This linkage gave rise to the clinical syndrome named frontotemporal dementia with parkinsonism linked to chromosome 17 or FTDP-17. The gene associated with FTDP-17 is the microtubule-associated binding protein tau (MAPT) gene. Mutations in the tau gene account for 7 to 50% of FTD cases with autosomal dominant inheritance patterns. 11, [15] [16] [17] [18] [19] [20] The variation in the percent of cases having mutations appears to be due to differing criteria for a positive family history. In our experience, if there are more than 3 family members with a fulminate history of FTD, there is an 80% probability of finding a tau mutation. More than 20 mutations have been identified in both the coding (exons) and noncoding regions of the tau gene.
In addition to mutations, a series of polymorphisms have been well described in the tau gene and extended to define 2 specific haplotypes (H1 and H2). It appears that the H1H1 tau haplotype has a greater prevalence in PSP, CBD, and some patients with FTD than in control subjects, and may act to increase susceptibility to these conditions. [21] [22] [23] [24] However, the mechanism for this association is not clear because the H1 haplotype is also very common in the general population. Because tau mutations only account for a percentage of familial FTD cases, clearly other FTD-causing genes exist. FTD has been linked to chromosome 3, a few FTD/ amyotrophic lateral sclerosis (ALS) families have been linked to chromosomes 9 and 17, and FTD with inclusion body myopathy and Paget disease have been linked to chromosome 9. [25] [26] [27] 36 Although some tau mutations show phenotypic correlations, in many cases clinical heterogeneity is observed even with the same tau mutation, suggesting that other genes and risk factors may play a role in the phenotype.
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DETERMINATION OF GENETIC ETIOLOGY OF FTD
Determination of genetic etiology of FTD is complicated by misdiagnoses, lost family histories, early death due to other causes (especially high-risk behaviors and suicide), and phenocopies with psychiatric etiologies. A comprehensive 3-generation pedigree is needed to evaluate genetic risk fully. A family history of dementia in any other relative should include age of onset of symptoms, the features of first symptoms, and speech/language changes of these relatives. In addition to a family history of dementia, any history of Parkinson disease or ALS must be included because parkin- Table 1) . FTD is a disease that affects the family with or without a family history of neurodegenerative disease. The early age of onset, the insidious nature of personality and/or language change, and a prolonged time until diagnosis create an unstable and often dysfunctional family environment. As a result, all family members are at risk for psychologic symptoms, symptoms that may mimic early symptoms of FTD. Determining whether a particular case is genetic is complicated by non-genetic phenocopies and by the difficulty of obtaining a good family history. Additionally, even when a known family history of FTD exists, these environmentally caused phenocopies make risk assessment and linkage analysis problematic.
Case 1: Problems Obtaining a Good Family History
Patient no. 1 was a 58-year-old man brought to the clinic by his wife for a second opinion on his diagnosis of AD. His wife was concerned that his condition was genetic because his mother, aunt, and grandmother had a history of dementia ( Fig. 1 ). She also felt that her husband's symptoms had persisted for over a decade and were not consistent with those of AD.
The patient's history was notable for long-term disinhibited sexual behavior and the inability to maintain employment. More recently he had developed word-finding problems, reduced speech output, and apathy. A neurologic examination revealed motor weakness; neuropsychological testing showed problems with executive function and semantic loss. He was ultimately diagnosed with FTD.
His wife's agenda included proving to her in-laws that the disease was organic and not due to stress from a bad marriage. She was also concerned that her own children might be at risk for inheriting the condition. Based on the history, the family was offered enrollment into a research genetic testing study for tau and other causal genes of FTD. The patient, his 3 adult children, and 3 siblings agreed to participate in genetic research. Family history information from the new individuals indicated that the patient's mother and aunt had an early-onset psychologic condition that progressed to dementia, but disagreed over the nature of the grandmother's condition. The grandmother's dementia came much later and was more consistent with AD because it began with memory problems rather than personality changes. All relatives of the patient had normal neuropsychological testing, MR images, and neurologic examinations. The siblings were reassured by the evaluation, and they and several other siblings agreed to donate DNA samples for genetic studies.
As of yet, no tau mutation or linkage has been found.
This case demonstrates how FTD families may have complex psychiatric histories that can complicate pedigree analysis (Fig. 1) . This case could demonstrate autosomal dominant inheritance; however, due to lack of medical documentation, the mother's and aunt's diagnoses are uncertain. In many families there is increased frequency of neurodegenerative disease that could be consistent with increased genetic risk, but not in the traditional Mendelian patterns. Genetic counseling for this family involved education about the disease and its ramifications. We stressed the subtleties of early symptoms and how stress does not cause these symptoms, but rather might occur as a result of them. We also discussed the importance of long-term psychologic counseling for family members living through the disease. The family was told about the difficulty of establishing a definite genetic etiology for the patient's disease because no medical records were available on his mother or aunt. All family members expressed a wish to know when and if our research eventually finds any genetic linkage.
Case 2: Phenocopies and Genetic Linkage
Patient 2, a 72-year-old man, was brought to the clinic by his daughter for evaluation of dementia. He was diagnosed Fig. 2) . Personality changes and abusive behaviors were not unusual for this family. Additionally there were multiple relatives with psychiatric and antisocial behavioral histories. The daughter wished to involve the family in clinical and genetic research. A total of 10 family members were fully evaluated with neuropsychological testing, neurologic examination, EMG, and brain MRI. Abnormal neuropsychological testing results and questionable MRI findings were revealed on several of the family members. However, evaluation was complicated in all cases by extensive drug and/or psychiatric histories, including pedophilia, arson, domestic abuse, bipolar disease, suicide, and depression. The extended family members donated approximately 30 blood samples for linkage analysis. Because none of the younger family members demonstrated any ALS symptoms, phenotyping was dependent on the neuropsychological evaluation and was complicated by the social and psychiatric histories. To date, no significant linkage has been found.
This case demonstrates how the psychologic dynamics of FTD families make genetic ascertainment difficult. When people are raised in families experiencing this disease, psychologic damage often results. Early diagnosis is vitally important to treat the affected person's symptoms and to moderate the disease's impact on the rest of the family.
Case 3: Phenotypic Variability
Patient 3 was a 50-year-old woman presenting for genetic counseling with a family history significant for a known FTDP-17 mutation. She had 2 first cousins with autopsy-confirmed FTD and an identified tau mutation.
As shown in the pedigree (Fig. 3) , each affected individual presented with a unique clinical phenotype despite having the same genetic mutation. One individual presented with disease onset in his early 40s and was clinically diagnosed as PSP. This individual had a rapidly progressive course and died at 47 years of age. The other individual presented with personality and behavioral changes and a progressive aphasia at a later age and was clinically diagnosed with FTD. She died at 60 years of age.
There were many issues to discuss in the context of genetic counseling for this family. If we assume that the father of the affected individuals had a dementia consistent with FTD, then the pedigree demonstrates autosomal dominant inheritance. Accordingly, the consultand's father would have been at 50% risk for inheriting the mutation. However, FIGURE 1. This pedigree represents the family history presented in case 1. The patient is marked with an arrow and the letter P. The legend in the figure defines the shading and patterns used to define affected individuals.
Goldman et al
The Neurologist • Volume 10, Number 5, September 2004 risk assessment for our patient was complicated because her father died of other causes before the age at which some of his relatives manifested symptoms. Additionally, the alcoholism in other family members may represent FTD-like symptoms. When alcoholism is present due to behavior changes manifesting FTD, it can be further discriminated from true alcoholism by age of onset and the patient's response to caregivers and physicians who ask the individuals to stop drinking. FTD patients tend to have a bizarre or inappropriate response, without any recognition that alcoholism is bad or that their behavior is inappropriate. Genetic counseling also involved discussion of the variable clinical phenotype in the family, the lack of prevention and effective treatment, the risks and benefits of predictive testing, and the difference between research and clinical genetic testing. The patient decided that at this time she was not interested in predictive testing for the mutation identified in her family. She worried that if a mutation were identified in her, she and her children might experience adverse emotional, social, and financial effects. She agreed to participate in genetic research studies with the understanding that she would not learn any information about her genetic status.
Case 4: Teasing Out the Normal Variants
Patient 4 was a 57-year-old woman who was referred for evaluation of possible FTD because of word-finding difficulty. During the visit the patient reported having "trouble with her memory." Specifically, she was not able to remember the names of family and friends. She also was having trouble understanding words during conversation and difficulty with concentration. These symptoms had progressed over the past 6 months. The patient also stated that she was concerned because she had observed similar problems in her mother and in an older sibling. Her maternal grandmother was reported to have died of a dementia at age 85. As a result of this family history, our patient was worried about an inherited condition.
A thorough neurocognitive examination was normal. Although occasional word-finding pauses were noted during conversation, these were no more frequent than in her age- Her performance on a quantitative measure of confrontation naming was within normal limits. MRI and PET were also within normal limits. Further analysis of her family history revealed that the patient's grandmother had a history of hypertension and died of stroke. The pedigree revealed no other neurologic conditions. The evaluation team felt the patient's anxiety over inheriting a dementia was the likely cause of her concentration problem that exacerbated her naming and short-term memory difficulty. The team reassured the patient that she was not, at that time, cognitively impaired and that her MRI was normal, and suggested ways that she might decrease her anxiety over this issue. This case demonstrates that some language and memory changes experienced with aging are normal; however, in the context of misinterpretations of family history and anxiety over changes, symptoms can be intensified and misdiagnoses can occur. Follow-up 2 years from presentation in these cases has revealed no change in language or memory versus individuals with an FTD or related condition, which would show decline on follow-up evaluation.
Genetic Counseling of Families
As with any adult-onset genetic disease, members of families with a known autosomal dominant family history of FTD are often worried about the future for themselves or their children. A vital role for the clinician when counseling such families is to educate them about the various presenting symptoms of the disease while reassuring them that psychiatric or behavioral problems are common and could be the result of living with someone with FTD or could be due to an unrelated cause, rather than early manifestations of the disease itself. Children and adolescents are often exposed to early disease symptoms in a parent. A parent's emotional blunting or disinhibited behaviors can scar young people for life and result in psychiatric problems. Unaffected family members may misinterpret these symptoms. Whenever possible, families dealing with FTD should be referred for psychologic counseling to help manage the stress and psychologic complexities of living with someone with this dementia.
Many family members of at-risk individuals wish to learn whether their family carries a causal gene for FTD. This is even true in families in which there is not a strong family history of FTD. The first step in providing genetic counseling to families is to obtain a detailed family medical history. This allows the clinician to identify the mode of inheritance, if any. Currently only limited clinical genetic testing exists for the tau gene, and the majority of testing that is available for familial FTD is on a research basis. Available genetic testing can be found on the following Web site: http://www.genetests. org. Currently clinical testing is available at University of 
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The Neurologist Before pursuing any genetic testing, the clinician should explain the genetics of FTD, including the relative incidence of sporadic versus genetic cases, the likelihood of finding a tau mutation, the difference between clinical and research testing, and the ramifications for other family members should a mutation be found. As stated earlier, mutations in tau only occur in about 7 to 50% of individuals with an autosomal dominant pattern of inheritance for FTD. Families must understand that a negative result for tau does not preclude the existence of a genetic etiology for the disease or a 50% recurrence risk in families with dominant inheritance. When a mutation in tau is identified, families should be counseled that these mutations are thought to be fully penetrant; however, the age of onset and spectrum of clinical symptoms cannot be predicted.
When no family history of FTD exists, the likelihood of finding a tau mutation is quite small, and therefore clinical genetic testing is not recommended. However, families often want to participate in genetic research with the hope of future results for their family and further understanding of the disease so that treatments might be discovered. Knowing that research is taking place gives families hope for the future.
To provide predictive genetic testing for unaffected family members, a mutation must be found in an affected individual. When a gene mutation is discovered, relatives wishing their own testing should be referred to a genetic counselor familiar with predictive testing for neurodegenerative disorders such as Huntington disease (HD). Genetic testing for HD has been available for well over 10 years, and physicians and genetic counselors have learned from early experience that such testing has many risks. Thus, counseling protocols have been developed to reduce the risk of adverse outcomes. As with HD, learning that one carries a gene for FTD can result in severe emotional consequences. 33 The HD protocol calls for several pretest counseling sessions that include baseline psychologic evaluation and neurologic testing (optional). 34 Result counseling should always be face to face with a support person present (an individual who is not at risk for the disease and who has been part of the pretest counseling), and further follow-up counseling should be available in person or by telephone. Families involved in research projects must understand that a research laboratory cannot give presymptomatic genetic results unless arrangements have been made with a clinical laboratory to comply with federal regulations.
A survey of at-risk individuals in a large family with a known tau mutation predisposing to pallido-ponto-nigral degeneration, an early name for FTDP-17, found that 50% of individuals were interested in testing. Primary reasons for testing were to further scientific research, to know if children were at risk, to reduce uncertainty about the future, and to plan for medical expenses. Of those who did not want to pursue testing, the primary reasons were to maintain hope, inability to cope with the stress and anxiety of a positive result, and fear of knowing that they were going to develop the disease. 35 Neuropsychological testing in asymptomatic FTDP-17 mutation carriers revealed cognitive changes and difficulties with executive functioning many years to decades earlier than non-mutation carriers in the same family. 7 This is important to remember in evaluation of at-risk individuals who are considering predictive genetic testing. Referral for psychologic counseling may be appropriate before testing.
Key issues for genetic counseling are summarized in Table 2 .
CONCLUSIONS
Frontotemporal dementia is a complex disease that has yet to be fully understood. This condition can have devastating effects on patients and their family members. When working with these families, clinicians must be sensitive to When no family history of FTD exists, the likelihood of finding a tau mutation is quite small. the psychologic consequences of the disease on family members, the resulting family dysfunction, and the fear of inheritance. Physicians are often too busy managing the medical symptoms to provide extensive genetic counseling. Referral of the patient and family for genetic counseling and psychologic/family counseling should be considered.
